VanEck Biotech ETF
BBH
83 hedge funds and large institutions have $294M invested in VanEck Biotech ETF in 2015 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 20 increasing their positions, 26 reducing their positions, and 11 closing their positions.
18% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 11
3.59% more ownership
Funds ownership: 41.64% → 45.23% (+3.6%)
2% more funds holding
Funds holding: 81 → 83 (+2)
12% less capital invested
Capital invested by funds: $333M → $294M (-$38.5M)
23% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 26
51% less call options, than puts
Call options by funds: $2.87M | Put options by funds: $5.85M
Top Buyers
| 1 |
Goldman Sachs
New York
|
+$17.8M |
| 2 |
VFAM
Valley Forge Asset Management
King Of Prussia,
Pennsylvania
|
+$6.31M |
| 3 |
Truist Financial
Charlotte,
North Carolina
|
+$4.84M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.68M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$3.74M |
Top Sellers
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
-$7.44M |
| 2 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
-$7.28M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$4.29M |
| 4 |
ECML
Eagle Capital Management (Louisiana)
Mandeville,
Louisiana
|
-$4.16M |
| 5 |
Morgan Stanley
New York
|
-$3.57M |
BBH Hedge Fund Activity: Q3 2015 in Review
83 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q3 2015, worth a combined $294M — down 12% from $333M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new BBH positions and 11 closed out — a net gain of 2 holders — while 20 added to existing stakes and 26 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $17.8M. The largest seller was Envestnet Asset Management, cutting an estimated $7.44M.
- 83 institutional investors held VanEck Biotech ETF (BBH) as of Q3 2015, up from 81 in Q2 2015.
- Funds reported $294M of VanEck Biotech ETF stock for Q3 2015, down 12% quarter-over-quarter.
- 13 funds opened new VanEck Biotech ETF positions in Q3 2015 and 11 closed out, a net change of +2 holders.
- The largest VanEck Biotech ETF buyer in Q3 2015 was Goldman Sachs, an estimated $17.8M added.
- The largest VanEck Biotech ETF seller in Q3 2015 was Envestnet Asset Management, an estimated $7.44M sold.
Based on aggregated 13F filings for Q3 2015.